Rezolute, Inc. RZLT
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Rezolute, Inc. is a late-stage rare disease company focused on developing therapies to improve outcomes for individuals with hypoglycemia caused by hyperinsulinism, including congenital and tumor forms. Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody that binds to an allos…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees75
TickerRZLT
Statistics
Market Cap$456.9M
Revenue (TTM)$0
Net Income-$74.4M
Net Margin—
EPS$-0.98
P/E-3.93
P/S—
P/B3.08
EV/EBITDA-2.99
ROE-81.7%
Dividend Yield—
Price$4.75
Data: Twelve Data · Revenue = mcap / P/S